

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection All software used is either freely available or commercially available:
ImageLab version 5.2.1
ImageJ 1.50i
Fiji/ImageJ version 2.1.0/1.53c
guava Soft 3.3

Data analysis All software used is either freely available or commercially available:
ImageJ 1.50i
Fiji/ImageJ version 2.1.0/1.53c
GraphPad Prism version 9.0.0 (86)
Ape-A plasmid Editor version 2.0.49.10
guava Soft 3.3
bowtie2 version 2.3.4.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The manuscript includes the following Data Availability Statement:

The riboseq and RNA-seq datasets in this study have been deposited in the NCBI SRA database under accession code [http://www.ncbi.nlm.nih.gov/bioproject/768478]. The riboseq and RNASeq source data generated in this study are provided in the Supplementary Information.

The manuscript includes the following Code Availability Statement:

All custom software used in this study is available at GitHub: <https://github.com/aurelioteleman/Teleman-Lab> [https://github.com/aurelioteleman/Teleman-Lab] and in the Zenodo repository (10.5281/zenodo.5751288).

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical sample-size calculation was performed. Instead, experiments were performed with 3 biological replicates, which from experience is sufficient to assure that the selected examples are representative and reproducible. If the effect size was small, additional biological replicates were performed to ensure reproducibility. For each experiment we clearly state the number of independent biological replicates in the manuscript.
Data exclusions	In Figure 4b f, luciferase reporter for CDKL5 produced very low values; therefore, values below 40 (=background) were excluded from the analysis.
Replication	All technically sound attempts at replication of all experiments were successful. The number of independent biological replicates is clearly stated in the manuscript in every case.
Randomization	In all cases cells were randomly pipetted into the various wells of the experiment for the different treatments.
Blinding	For analysis of microscopy images in Figures 4 and 5 and Suppl. Figures 1, 2, 6 and 7 the investigator was not blinded to group allocation because the differences between the different groups were immediately obvious (cell morphology, mitotic accumulation, apoptotic cells). Also for the other experiments the investigators were not blinded to group allocation during data collection because the measurements are quantitative and difficult to influence by investigator bias.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies used	<p>ABLIM1 (WB: 1:1000, IF: 1:500, rabbit, bethyl-biomol A302-237-T), β-Actin (1:5000, mouse, Sigma #A2228), ATF-4 (1:1000, rabbit, Cell Signalling #11815), Caspase 3 (1:1000, rabbit, Cell Signalling #9662), CDKL5 (WB: 1:1000, IF: 1:500, rabbit, abcam ab22453), CDT1 (1:1000, rabbit, Cell Signalling #8064), cleaved Caspase 3 (WB: 1:1000, flow cytometry 1:100, rabbit, Cell Signalling #9664), CUL1 (1:500, mouse, Invitrogen #32-2400), cyclin A2 (1:1000, rabbit, Cell Signalling #91500), cyclin B1 (1:1000, mouse, Cell Signaling #12231), cyclin E1 (1:1000, rabbit, Cell Signalling #20808), DENR (WB and IF: 1:2000, guinea pig, in-house production), pDENR_Ser73 (WB: 1:500, IF: 1:200, rabbit, custom-made by innovagen AB, Lund, Sweden), DUSP4 (WB: 1:1000, IF: 1:500, rabbit, abcam ab216576), FLAG (1:1000, rabbit, Sigma #F7425), FLAG-M2 (1:1000, mouse, Sigma #F3165), gamma-Tubulin (1:1000, Abcam, #ab27074), GAPDH (1:2000, rabbit, Cell Signalling #2118), Geminin (1:1000, rabbit, Cell Signalling #52508), pHH3 (Serine 10) (for WB: 1:500, rabbit, Cell Signaling #9701; for flow cytometry: 1:100, mouse, Cell Signalling #9706S), MAP2K6 (WB: 1:1000, IF: 1:500, rabbit, Cell Signalling #8550), MCTS1 (1:1000, guinea pig, in-house production), a-raf (1:1000, rabbit, Cell Signaling #4432), c-raf (1:1000, rabbit, Cell Signaling #9422), ERK1/2 (1:1000, rabbit, Cell Signaling #4695), GST-HRP conjugate (1:5000, goat, GE Healthcare #RPN1236), pERK1/2 (T202/Y204) (1:1000, rabbit, Cell Signaling #4370), p-p90RSK (T359/Y363) (1:1000, rabbit, Cell Signaling #9344), RSK1/2/3 (1:1000, rabbit, Cell Signaling #14813).</p>
Validation	<p>ABLIM1 (WB: 1:1000, IF: 1:500, rabbit, bethyl-biomol A302-237-T): WB manufacturer's website and siRNA-mediated knockdown, IF siRNA-mediated knockdown β-Actin (1:5000, mouse, Sigma #A2228): WB manufacturer's website ATF-4 (1:1000, rabbit, Cell Signalling #11815): WB and IF manufacturer's website Caspase 3 (1:1000, rabbit, Cell Signalling #9662): WB manufacturer's website CDKL5 (WB: 1:1000, IF: 1:500, rabbit, abcam ab22453): WB manufacturer's website and siRNA-mediated knockdown, IF siRNA-mediated knockdown CDT1 (1:1000, rabbit, Cell Signalling #8064): WB manufacturer's website cleaved Caspase 3 (WB: 1:1000, flow cytometry 1:100, rabbit, Cell Signalling #9664): WB and flow cytometry manufacturer's website CUL1 (1:500, mouse, Invitrogen #32-2400): WB manufacturer's website cyclin A2 (1:1000, rabbit, Cell Signalling #91500): WB manufacturer's website cyclin B1 (1:1000, mouse, Cell Signaling #12231): WB manufacturer's website cyclin E1 (1:1000, rabbit, Cell Signalling #20808): WB manufacturer's website DENR (WB and IF: 1:2000, guinea pig, in-house production): KO cells within this publication (WB, IF) pDENR_Ser73 (WB: 1:500, IF: 1:200, rabbit, custom-made by innovagen AB, Lund, Sweden): KO cells within (WB) and besides (IF) this publication DUSP4 (WB: 1:1000, IF: 1:500, rabbit, abcam ab216576): WB and IF manufacturer's website, IF siRNA-mediated knockdown FLAG (1:1000, rabbit, Sigma #F7425): WB manufacturer's website FLAG-M2 (1:1000, mouse, Sigma #F3165): WB manufacturer's website GAPDH (1:2000, rabbit, Cell Signalling #2118): WB manufacturer's website gamma-Tubulin (1:1000, Abcam #27074): IF manufacturer's website Geminin (1:1000, rabbit, Cell Signalling #52508): WB manufacturer's website pHH3 (Serine 10) (for WB: 1:500, rabbit, Cell Signaling #9701): WB manufacturer's website pHH3 (Serine 10) (for flow cytometry: 1:100, mouse, Cell Signalling #9706S): flow cytometry manufacturer's website MAP2K6 (WB: 1:1000, IF: 1:500, rabbit, Cell Signalling #8550): WB manufacturer's website, IF siRNA-mediated knockdown MCTS1 (1:1000, guinea pig, in-house production): KO cells in our lab a-raf (1:1000, rabbit, Cell Signaling #4432): WB manufacturer's website c-raf (1:1000, rabbit, Cell Signaling #9422): WB manufacturer's website ERK1/2 (1:1000, rabbit, Cell Signaling #4695): WB manufacturer's website GST-HRP conjugate (1:5000, goat, GE Healthcare #RPN1236): WB manufacturer's website pERK1/2 (T202/Y204) (1:1000, rabbit, Cell Signaling #4370): WB manufacturer's website p-p90RSK (T359/Y363) (1:1000, rabbit, Cell Signaling #9344): WB manufacturer's website RSK1/2/3 (1:1000, rabbit, Cell Signaling #14813): WB manufacturer's website</p>

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	HeLa, MCF7 and U2OS: ATCC
Authentication	HeLa, MCF7 and U2OS cells were not further validated. DENR_KO HeLa cells were authenticated by sequencing of the genomic locus and Western Blot.
Mycoplasma contamination	All cell lines tested negative for mycoplasma.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used in this study.

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Exponentially growing, untreated HeLa cells were trypsinized, spun down, washed twice in PBS, resuspended in Ethanol 70% and then kept at -20°C for 3hrs to several days. Hence, cells were washed twice in PBS, spun down and resuspended in PBS containing Triton X-100 0.25%. After incubation on ice for 15 minutes, cell were washed again in PBS and resuspended in PBS containing BSA 1% and primary antibodies at the indicated dilutions. Cells were incubated o/n at 4°C during gentle shaking, then washed in PBS, resuspended in PBS containing the indicated fluorescent secondary antibodies at a dilution of 1/250 and incubated at room temperature in the dark for 30 minutes during gentle shaking. Finally cells were washed in PBS again and resuspended in PBS for immediate analysis.

Instrument

guava easyCyte HT

Software

guava Soft 3.3

Cell population abundance

Total cells (no doublets, no debris): 10.000-40.000; Mitotic cells (pHH3 positive): 6.000-16.000; Mitotic apoptosis (CC3 and pHH3 positive): 20-300 cells

Gating strategy

1) FSC vs SSC: gate out doublets and debris
2) Yellow-G >10^{2.4}: CC3 positive
3) Green-B > 10³: pHH3 positive

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.